Wockhardt Limited

NSE WOCKPHARMA.NS

Wockhardt Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2024: USD 40.04 M

Wockhardt Limited Net Cash Used Provided By Financing Activities is USD 40.04 M for the year ending March 31, 2024, a 204.48% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Wockhardt Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2023 was USD -38.33 M, a -309.87% change year over year.
Wockhardt Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2022 was USD -9.35 M, a 94.15% change year over year.
Wockhardt Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2021 was USD -159.90 M, a -77.31% change year over year.
Wockhardt Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2020 was USD -90.18 M, a 19.29% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NSE: WOCKPHARMA.NS

Wockhardt Limited

CEO	Dr. Habil Fakhruddin Khorakiwala
IPO Date	July 1, 2002
Location	India
Headquarters	Wockhardt Towers
Employees	2,386
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, the United Kingdom, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules. The company's biopharmaceutical products include Glaritus, an insulin analog; Wosulin, an r-DNA insulin; Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. It also provides contract manufacturing services for sterile injectables, lyophilization, and other dosage forms; and research services. The company was founded in 1967 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.

Key trends

Past 5 years